408-854-1883 starts at $30 per hr home care

Affordable in home care | starts at $28 per hr

What is something I can say to myself to help me stop drinking alchohol?

My answer to What is something I can say to myself to help me stop drinking alchohol?

Answer by Connie b. Dellobuono:

Do you want to see your great grandchildren and attend their wedding?

Do you not want to be bed-ridden during old age?

Do you want to slow down the aging process?

Do you want not to go broke from paying high medical bills as a result of many diseases caused by alcohol addiction?

And many more questions, like dancing at age 95, travelling at age 98 and many activities you can do during old age and not encumbered or wheel chair bound because of the many other diseases caused by alcohol addiction…

What is something I can say to myself to help me stop drinking alchohol?

I took 30 mg of Ritalin and 8 hours later I took some sips of beer. Was that dangerous?

My answer to I took 30 mg of Ritalin and 8 hours later I took some sips of beer. Was that dangerous?

Answer by Connie b. Dellobuono:

Alcohol and grapefruits potentiates medications (doubles the strength).

Methylphenidate taken orally has a bioavailability of 11–52% with a duration of peak action around 2–4 hours for instant release (i.e. Ritalin), 3–8 hours for sustained release (i.e. Ritalin SR), and 8–12 hours for extended release (i.e. Concerta). The half-life of methylphenidate is 2–3 hours, depending on the individual. The peak plasma time is achieved at about 2 hours.

Dextromethylphenidate is much more bioavailable than levomethylphenidate when administered orally, and is primarily responsible for the psychoactivity of racemicmethylphenidate.

Contrary to the expectation, taking methylphenidate with a meal speeds absorption.

Methylphenidate is metabolized into ritalinic acid by CES1A1. Dextromethylphenidate is selectively metabolized at a slower rate than levomethylphenidate


From Wiki

Drugs, Genes and ADHD

ADHD drug #4: Concerta/Ritalin/Daytrana/Biphentin (methylphenidate)

Genes of Interest: Carboxylesterase 1 (also referred to as "CES1"), DAT (refer to ADHD drug #2: Adderall section for DAT's genetic location)

Carboxylesterase 1: Although the affected form of this enzyme, which is coded for by a gene on the 16th chromosome, is relatively rare, some key studies have indicated that deficiencies in the CES1 enzyme can be coded from specific forms of this gene. These rare, low-functioning gene-mutation forms of Carboxylesterase 1 result in extremely poor methylphenidate metabolism, resulting in a buildup of abnormally high levels of the drug in individuals with this enzymatically-deficient form.

In addition to their effects on amphetamines such as Adderall or Dexedrine, variations (often referred to in the literature as "polymorphisms") in the DAT gene also play a role in the response to methylphenidate. A Korean study found that a specific allele (the 10-repeat allele, which is the same form as the "high-risk" 480 base-pair allele mentioned earlier in the amphetamines section) predicted a poor response to methylphenidate.

Interestingly, however, several Irish studies suggest the exact opposite: the "high-risk" 10-repeat 480 base pair form of the DAT gene may produce larger amounts of the DAT protein (which shuttles essential dopamine out of the gaps between the cells, the opposite effect of what one wants if they suffer from ADHD), so the higher levels of expression of this transporter may make it a better candidate for methylphenidate.

Another Irish study may help resolve some of this discrepancy. It found that individuals with the so-called "high-risk" form of the DAT gene mentioned above exhibit a more positive response to treatment with methylphenidate with regards to treating their attentional symptoms based on the left side of the brain. Left sided inattention can be a

reflection of brain damage or brain asymmetry, the latter being a common trait in the ADHD population. It should be worth noting thatmethylphenidate has been an effective treatment method for improving cognitive processes for those suffering from traumatic brain injuries.

I took 30 mg of Ritalin and 8 hours later I took some sips of beer. Was that dangerous?

Texas maternal mortality rate up by 25% from 2011 -2012

Apparently, the researchers did some adjusting of their own. According to the Texas Department of State Health Services (DSHS), maternal mortality rates have been alarmingly increasing for years. That “modest increase,” lead researcher Marian MacDorman imagines, was a huge increase. In 2000, the MMR was 10.5 maternal deaths per 100,000 live births (equating to 30 tragic deaths). By 2009, this rate had nearly tripled to 28.9 maternal deaths per 100,000 live births (resulting in 116 deaths). That’s a “modest increase”? In 2010, the MMR actually decreased to 24.6.

Then, MacDorman et al claimed: “Texas had a sudden increase in 2011-2012.” If by sudden they mean over ten years of significant increases … sure. They completely ignored the fact that from 2010 to 2011, the MMR rose from 24.6 to 30.7 (an increase of about 25 percent). From 2011 to 2012, the increase was only 3%, rising to a rate of 31.6 … not doubling! That didn’t stop Slate.com and a host of media outlets from declaring: “After Texas Slashed Its Family Planning Budget, Maternal Deaths Almost Doubled.” In 2013 it rose another 25 percent to 39.5 (claiming the lives of 153 women).

Here’s the clincher, though. Texas’ MMR dropped in 2014 in rate and total maternal deaths.


Women in childbearing years should have monthly prenatals with nurse midwives/OBs and avoid drugs (including opioids during pregnancy and labor).

Tryptophan – Niacin – NAD = Anti-aging

tryp foodtryptryptophan and niacin

Chocolate, oats, dried dates, milk, yogurt, cottage cheese, red meat, eggs, fish, poultry, sesame, chickpeas, almonds, sunflower seeds, pumpkin seeds, buckwheat, spirulina, bananas, and peanuts.

Tryptophan

For many organisms (including humans), tryptophan is needed to prevent illness or death, but cannot be synthesized by the organism and must be ingested; in short, it is an essential amino acid. Amino acids, including tryptophan, act as building blocks in protein biosynthesis, and proteins are required to sustain life. In addition, tryptophan functions as a biochemical precursor for the following compounds (see also figure to the right):

  • Serotonin (a neurotransmitter), synthesized via tryptophan hydroxylase.[9][10] Serotonin, in turn, can be converted to melatonin (a neurohormone), via N-acetyltransferase and 5-hydroxyindole-O-methyltransferase activities.[11]
  • Niacin, also known as vitamin B3, is synthesized from tryptophan via kynurenine and quinolinic acids as key biosynthetic intermediates.[12]
  • Auxins (a class of phytohormones) are synthesized from tryptophan.[13]
  • The disorder fructose malabsorption causes improper absorption of tryptophan in the intestine, reduced levels of tryptophan in the blood,[14] and depression.[15] Some studies did not find reduced tryptophan in cases of lactose maldigestion.[14]
  • Niacin and its derivative nicotinamide are dietary precursors of nicotinamide adenine dinucleotide (NAD), which can be phosphorylated (NADP) and reduced (NADH and NADPH). NAD functions in oxidation-reduction (redox) reactions and non-redox reactions. (More information)
  • Pellagra is the disease of severe niacin deficiency. It is characterized by symptoms affecting the skin, the digestive system, and the nervous system and can lead to death if left untreated. (More information)
  • Dietary tryptophan can be converted to niacin, although the efficiency of conversion is low in humans and affected by deficiencies in other nutrients. (More information)
  • Causes of niacin deficiency include inadequate oral intake, poor bioavailability from unlimed grains, defective tryptophan absorption, metabolic disorders, and the long-term use of chemotherapeutic treatments. (More information)
  • The requirements for niacin are based on the urinary excretion of niacin metabolites. (More information)
  • NAD is the sole substrate for PARP enzymes involved in DNA repair activity in response to DNA strand breaks; thus, NAD is critical for genome stability. Several studies, mostly using in vitro and animal models, suggest a possible role for niacin in cancer prevention. Nevertheless, large studies are needed to investigate the association between niacin deficiency and cancer risk in human populations. (More information)
  • Despite promising initial results, nicotinamide administration has failed to prevent or delay the onset of type 1 diabetes in high-risk relatives of type 1 diabetics. Future research might explore the use of nicotinamide in combined therapy and evaluate activators of NAD-dependent enzymes. (More information)
  • At pharmacologic doses, niacin, but not nicotinamide, improves the lipid profile and reduces coronary events and total mortality in patients at high risk for coronary heart disease. Several clinical trials have explored the cardiovascular benefit of niacin in combination with other lipid-lowering medications. (More information)
  • Elevated tryptophan breakdown and niacin deficiency have been reported in HIV-positive people. This population is also at high risk for cardiovascular disease, and current data show that they could benefit from niacin supplementation. (More information)
  • The tolerable upper intake level (UL) for niacin is based on skin flushing, niacin’s most prominent side effect. A new drug, laropiprant, has been developed to reduce skin flushing. Adverse effects have also been reported with pharmacologic doses of niacin administrated alone or in combination with other lipid-lowering medications. (More information)
  • Niacin is a water-soluble vitamin, which is also known as nicotinic acid or vitamin B3. Nicotinamide is the derivative of niacin and used by the body to form the coenzymes nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). The chemical structures of the various forms of niacin are shown (Figure 1). None of the forms are related to the nicotine found in tobacco, although their names are similar (1).

Function

  • Oxidation-reduction (redox) reactions
  • Living organisms derive most of their energy from oxidation-reduction (redox) reactions, which are processes involving the transfer of electrons. Over 400 enzymes require the niacin coenzymes, NAD and NADP, mainly to accept or donate electrons for redox reactions (2). NAD functions most often in energy-producing reactions involving the degradation (catabolism) of carbohydrates, fats, proteins, and alcohol. NADP functions more often in biosynthetic (anabolic) reactions, such as in the synthesis of all macromolecules, including fatty acids and cholesterol (1, 3).

Non-redox reactions

  • The niacin coenzyme, NAD, is the substrate (reactant) for at least four classes of enzymes that separate the nicotinamide moiety from NAD and transfer ADP-ribose to acceptors.
  • Mono-ADP-ribosyltransferase enzymes were first discovered in certain bacteria, where they mediate the action of toxins, such as cholera and diptheria. In mammalian cells, these enzymes transfer an ADP-ribose residue from NAD to a specific amino acid of a target protein, with the creation of an ADP-ribosylated protein and the release of nicotinamide. Mono ADP-ribosylation reactions reversibly modify the activity of acceptor proteins, such as G-proteins that bind guanosine-5′-triphosphate (GTP) and act as intermediaries in a number of cell-signaling pathways (4).
  • Poly-ADP-ribose polymerases (PARPs) are enzymes that catalyze the transfer of polymers of ADP-ribose from NAD to acceptor proteins. PARPs appear to function in DNA repair and stress responses, cell signaling, transcription, regulation, apoptosis, chromatin structure, and cell differentiation, suggesting a role for NAD in cancer prevention (3). At least six different PARPs have been identified, and although their functions are not yet fully understood, their existence indicates a potential for considerable consumption of NAD (5, 6).
  • A new nomenclature has been proposed for enzymes catalyzing ADP-ribosylation: The PARP family was renamed ARTD, while ARTC designates the mono ADP-ribosyltransferase family (6).
  • ADP-ribosylcyclases catalyze the formation of cyclic ADP-ribose from ADP-ribose. Cyclic ADP-ribose works within cells to provoke the release of calcium ions from internal storage sites and probably also plays a role in cell signaling (1).
  • Sirtuins are a class of NAD-dependent deacetylase enzymes that remove acetyl groups from the acetylated lysine residues of target proteins. During the deacetylation process, an ADP-ribose is added to the acetyl group to produce O-acetyl-ADP-ribose. Both acetylation and ADP-ribosylation are known post-translational modifications that affect protein activities. The initial interest in sirtuins followed the discovery that their activation could mimic calorie restriction, which has been shown to increase lifespan in lower organisms. Such a role in mammals is controversial, although sirtuins are energy-sensing regulators involved in signaling pathways that could play important roles in delaying the onset of age-related diseases (e.g., cardiovascular disease, cancer, dementia, arthritis). To date, the spectrum of their biological functions include gene silencing, DNA damage repair, cell cycle regulation, and cell differentiation (7).

Summary

  • Niacin and its derivative nicotinamide are dietary precursors of nicotinamide adenine dinucleotide (NAD), which can be phosphorylated (NADP) and reduced (NADH and NADPH). NAD functions in oxidation-reduction (redox) reactions and non-redox reactions. (More information)
  • Pellagra is the disease of severe niacin deficiency. It is characterized by symptoms affecting the skin, the digestive system, and the nervous system and can lead to death if left untreated. (More information)
  • Dietary tryptophan can be converted to niacin, although the efficiency of conversion is low in humans and affected by deficiencies in other nutrients. (More information)
  • Causes of niacin deficiency include inadequate oral intake, poor bioavailability from unlimed grains, defective tryptophan absorption, metabolic disorders, and the long-term use of chemotherapeutic treatments. (More information)
  • The requirements for niacin are based on the urinary excretion of niacin metabolites. (More information)
  • NAD is the sole substrate for PARP enzymes involved in DNA repair activity in response to DNA strand breaks; thus, NAD is critical for genome stability. Several studies, mostly using in vitro and animal models, suggest a possible role for niacin in cancer prevention. Nevertheless, large studies are needed to investigate the association between niacin deficiency and cancer risk in human populations. (More information)
  • Despite promising initial results, nicotinamide administration has failed to prevent or delay the onset of type 1 diabetes in high-risk relatives of type 1 diabetics. Future research might explore the use of nicotinamide in combined therapy and evaluate activators of NAD-dependent enzymes. (More information)
  • At pharmacologic doses, niacin, but not nicotinamide, improves the lipid profile and reduces coronary events and total mortality in patients at high risk for coronary heart disease. Several clinical trials have explored the cardiovascular benefit of niacin in combination with other lipid-lowering medications. (More information)
  • Elevated tryptophan breakdown and niacin deficiency have been reported in HIV-positive people. This population is also at high risk for cardiovascular disease, and current data show that they could benefit from niacin supplementation. (More information)
  • The tolerable upper intake level (UL) for niacin is based on skin flushing, niacin’s most prominent side effect. A new drug, laropiprant, has been developed to reduce skin flushing. Adverse effects have also been reported with pharmacologic doses of niacin administrated alone or in combination with other lipid-lowering medications. (More information)
  • Niacin is a water-soluble vitamin, which is also known as nicotinic acid or vitamin B3. Nicotinamide is the derivative of niacin and used by the body to form the coenzymes nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). The chemical structures of the various forms of niacin are shown (Figure 1). None of the forms are related to the nicotine found in tobacco, although their names are similar (1).
  • Figure 1. Chemical Structures of Niacin and Related Compounds. Niacin is also known as nicotinic acid or vitamin B3. nicotinamide is the derivative of niacin that is used to form the coenzymes NAD and NADP.

Function

  • Oxidation-reduction (redox) reactions
  • Living organisms derive most of their energy from oxidation-reduction (redox) reactions, which are processes involving the transfer of electrons. Over 400 enzymes require the niacin coenzymes, NAD and NADP, mainly to accept or donate electrons for redox reactions (2). NAD functions most often in energy-producing reactions involving the degradation (catabolism) of carbohydrates, fats, proteins, and alcohol. NADP functions more often in biosynthetic (anabolic) reactions, such as in the synthesis of all macromolecules, including fatty acids and cholesterol (1, 3).

Non-redox reactions

  • The niacin coenzyme, NAD, is the substrate (reactant) for at least four classes of enzymes that separate the nicotinamide moiety from NAD and transfer ADP-ribose to acceptors.
  • Mono-ADP-ribosyltransferase enzymes were first discovered in certain bacteria, where they mediate the action of toxins, such as cholera and diptheria. In mammalian cells, these enzymes transfer an ADP-ribose residue from NAD to a specific amino acid of a target protein, with the creation of an ADP-ribosylated protein and the release of nicotinamide. Mono ADP-ribosylation reactions reversibly modify the activity of acceptor proteins, such as G-proteins that bind guanosine-5′-triphosphate (GTP) and act as intermediaries in a number of cell-signaling pathways (4).
  • Poly-ADP-ribose polymerases (PARPs) are enzymes that catalyze the transfer of polymers of ADP-ribose from NAD to acceptor proteins. PARPs appear to function in DNA repair and stress responses, cell signaling, transcription, regulation, apoptosis, chromatin structure, and cell differentiation, suggesting a role for NAD in cancer prevention (3). At least six different PARPs have been identified, and although their functions are not yet fully understood, their existence indicates a potential for considerable consumption of NAD (5, 6).
  • A new nomenclature has been proposed for enzymes catalyzing ADP-ribosylation: The PARP family was renamed ARTD, while ARTC designates the mono ADP-ribosyltransferase family (6).
  • ADP-ribosylcyclases catalyze the formation of cyclic ADP-ribose from ADP-ribose. Cyclic ADP-ribose works within cells to provoke the release of calcium ions from internal storage sites and probably also plays a role in cell signaling (1).
  • Sirtuins are a class of NAD-dependent deacetylase enzymes that remove acetyl groups from the acetylated lysine residues of target proteins. During the deacetylation process, an ADP-ribose is added to the acetyl group to produce O-acetyl-ADP-ribose. Both acetylation and ADP-ribosylation are known post-translational modifications that affect protein activities. The initial interest in sirtuins followed the discovery that their activation could mimic calorie restriction, which has been shown to increase lifespan in lower organisms. Such a role in mammals is controversial, although sirtuins are energy-sensing regulators involved in signaling pathways that could play important roles in delaying the onset of age-related diseases (e.g., cardiovascular disease, cancer, dementia, arthritis). To date, the spectrum of their biological functions include gene silencing, DNA damage repair, cell cycle regulation, and cell differentiation (7).

Deficiency: Pellagra

  • The late stage of severe niacin deficiency is known as pellagra. Early records of pellagra followed the widespread cultivation of corn in Europe in the 1700s (1). The disease is generally associated with poorer social classes whose chief dietary staple consisted of cereals like corn or sorghum. Pellagra was also common in the southern United States during the early 1900s where income was low and corn products were a major dietary staple (8).
  • Interestingly, pellagra was not known in Mexico, where corn was also an important dietary staple and much of the population was also poor. In fact, corn contains appreciable amounts of niacin, but it is present in a bound form that is not nutritionally available to humans. The traditional preparation of corn tortillas in Mexico involves soaking the corn in a lime (calcium oxide) solution, prior to cooking. Heating the corn in an alkaline solution results in the release of bound niacin, increasing its bioavailability (9).
  • The most common symptoms of niacin deficiency involve the skin, the digestive system, and the nervous system (3). The symptoms of pellagra are commonly referred to as the three D’s: dermatitis, diarrhea, and dementia. A fourth D, death, occurs if pellagra is left untreated (10). In the skin, a thick, scaly, darkly pigmented rash develops symmetrically in areas exposed to sunlight. In fact, the word “pellagra” comes from “pelle agra,” the Italian phrase for rough or raw skin. Symptoms related to the digestive system include inflammation of the mouth and tongue (“bright red tongue”), vomiting, constipation, abdominal pain, and ultimately, diarrhea.
  • Gastrointestinal disorders and diarrhea contribute to the ongoing malnourishment of the subjects. Neurologic symptoms include headache, apathy, fatigue, depression, disorientation, and memory loss and are more consistent with delirium than with the historically described dementia (11). Disease presentations vary in appearance since the classic triad rarely presents in its entirety. The absence of dermatitis, for example, is known as pellagra sine pellagra.

Treatment of pellagra

  • To treat pellagra, the World Health Organization (WHO) recommends administering nicotinamide to avoid the flushing commonly caused by niacin (see Safety). Treatment guidelines suggest using 300 mg nicotinamide per day orally in divided doses, or 100 mg per day parenterally in divided doses, for three to four weeks (12, 13). Because patients with pellagra often display additional vitamin deficiencies, administration of a vitamin B-complex preparation is advised.

Tryptophan metabolism

  • In addition to its synthesis from dietary niacin, NAD can be synthesized from the dietary amino acid tryptophan via the kynurenine pathway (see Figure 2 below). The relative ability to make this conversion varies greatly from mice to humans. The first step is catalyzed by the extrahepatic enzyme indoleamine 2,3-dioxygenase (IDO), which is responsible for the oxidative cleavage of tryptophan. The chronic stimulation of tryptophan oxidation, mediated by an increased activity of IDO and/or inadequate niacin levels, is observed in a number of diseases, including human immunodeficiency virus (HIV) infection (see HIV/AIDS). In healthy individuals, less than 2% of dietary tryptophan is converted to NAD by this tryptophan oxidation pathway (14).
  • Tryptophan metabolism plays an essential regulatory role by mediating immunological tolerance of the fetus during pregnancy (15). It is now understood that tryptophan oxidation in the placenta drives a physiologic tryptophan depletion that impairs the function of nearby maternal T-lymphocytes and prevents the rejection of the fetus. However, the synthesis of niacin from tryptophan is a fairly inefficient pathway that depends on enzymes requiring vitamin B6 and riboflavin, as well as an enzyme containing heme (iron). On average, 1 milligram (mg) of niacin can be synthesized from the ingestion of 60 mg of tryptophan. The term “niacin equivalent” (NE) is used to describe the contribution to dietary intake of all the forms of niacin that are available to the body.
  • Thus, 60 mg of tryptophan are considered to be 1 mg NE. However, studies of pellagra in the southern US during the early twentieth century indicated that the diets of many individuals who suffered from pellagra contained enough NE to prevent pellagra (10), challenging the idea that 60 mg of dietary tryptophan are equivalent to 1 mg of niacin. In particular, one study in young men found that the tryptophan content of the diet had no effect on the decrease in red blood cell niacin content that resulted from low dietary niacin (16).

Causes of niacin deficiency

  • Niacin deficiency or pellagra may result from inadequate dietary intake of niacin and/or tryptophan. As mentioned above, other nutrient deficiencies may also contribute to the development of niacin deficiency. Niacin deficiency, often associated with malnutrition, is observed in the homeless population, in individuals suffering from anorexia nervosa or obesity, and in consumers of diets high in maize and poor in animal proteins (17-20).
  • Patients with Hartnup’s disease, a hereditary disorder resulting in defective tryptophan absorption, have developed pellagra (3). Other malabsorptive states that can lead to pellagra include Crohn’s disease and megaduodenum (21, 22). Carcinoid syndrome, a condition of increased secretion of serotonin and other catecholamines by carcinoid tumors, may also result in pellagra due to increased utilization of dietary tryptophan for serotonin rather than niacin synthesis. Further, prolonged treatment with the anti-tuberculosis drug Isoniazid has resulted in niacin deficiency (23).
  • Other pharmaceutical agents, including the immunosuppressive drugs Azathioprine and 6-Mercaptopurine, the anti-cancer drug 5-Fluorouracil, and Carbidopa, a drug given to people with Parkinson’s disease, are known to increase the reliance on dietary niacin by interfering with the tryptophan-kinurenine-niacin pathway. Finally, other populations at risk for niacin deficiency include dialysis patients, cancer patients (13, 24), individuals suffering from chronic alcoholism (11), and people with HIV (see HIV/AIDS).

Disease Prevention: Cancer

  • Studies of cultured cells (in vitro) provide evidence that NAD content influences mechanisms that maintain genomic stability. Loss of genomic stability, characterized by a high rate of damage to DNA and chromosomes, is a hallmark of cancer (28). The current understanding is that the pool of NAD is decreased during niacin deficiency and that it affects the activity of NAD-consuming enzymes rather than redox and metabolic functions (29). Among NAD-dependent reactions, poly ADP-ribosylations catalyzed by PARP enzymes are critical for the cellular response to DNA injury. After DNA damage, PARPs are activated.
  • The subsequent poly ADP-ribosylations of a number of signaling and structural molecules by PARPs were shown to facilitate DNA repair at DNA strand breaks. Cellular depletion of NAD has been found to decrease levels of the tumor suppressor protein p53, a target for poly ADP-ribosylation, in human breast, skin, and lung cells (27). The expression of p53 was also altered by niacin deficiency in rat bone marrow cells (30). Impairment of DNA repair caused by niacin deficiency could lead to genomic instability and drive tumor development in rat models (31, 32).
  • Both PARPs and sirtuins have been recently involved in the maintenance of heterochromatin, a chromosomal domain associated with genome stability, as well as in transcriptional gene silencing, telomere integrity, and chromosome segregation during cell division (33, 34). Neither the cellular NAD content nor the dietary intake of NAD precursors (niacin and tryptophan) necessary for optimizing protective responses following DNA damage has been determined, but both are likely to be higher than that required for the prevention of pellagra.

Bone marrow

  • Cancer patients often suffer from bone marrow suppression following chemotherapy, given that bone marrow is one of the most proliferative tissues in the body and thus a primary target for chemotherapeutic agents. Niacin deficiency was found to decrease bone marrow NAD and poly-ADP-ribose levels and increase the risk of chemically induced leukemia in rats (35). Conversely, a pharmacologic dose of niacin was able to increase NAD and poly ADP-ribose in bone marrow and decrease the development of leukemia in rats (36).
  • It has been suggested that niacin deficiency often observed in cancer patients could sensitize bone marrow tissue to the suppressive effect of chemotherapy. However, little is known regarding cellular NAD levels and the prevention of DNA damage or cancer in humans. One study in two healthy individuals involved elevating NAD levels in blood lymphocytes by supplementation with 100 mg/day niacin for eight weeks.
  • Compared to non-supplemented individuals, the supplemented individuals had reduced DNA strand breaks in lymphocytes exposed to free radicals in a test tube assay (37). However, niacin supplementation of up to 100 mg/day in 21 healthy smokers failed to provide any evidence of a decrease in cigarette smoke-induced genetic damage in blood lymphocytes compared to placebo (38).
  • More recently, the frequency of chromosome translocation was used to evaluate DNA damage in peripheral blood lymphocytes of 82 pilots chronically exposed to ionizing radiation, a known human carcinogen. In this observational study, the rate of chromosome aberrations was significantly lower in subjects with high (28.4 mg/day) compared to low (20.5 mg/day) dietary niacin intake (39).

Upper digestive tract

  • Generally, relationships between dietary factors and cancer are established first in epidemiological studies and followed up by basic cancer research at the cellular level. In the case of niacin, research on biochemical and cellular aspects of DNA repair has stimulated an interest in the relationship between niacin intake and cancer risk in human populations (40). A large case-control study found increased consumption of niacin, along with antioxidant nutrients, to be associated with decreased incidence of oral (mouth), pharyngeal (throat), and esophageal cancers in northern Italy and Switzerland (41, 42). An increase in daily niacin intake of 6.2 mg was associated with about a 40% decrease in cases of cancers of the mouth and throat, while a 5.2 mg increase in daily niacin intake was associated with a similar decrease in cases of esophageal cancer.

Skin

  • Niacin deficiency can lead to severe sunlight sensitivity in exposed skin. Given the implication of NAD-dependent enzymes in DNA repair, there has been some interest in the effect of niacin on skin health. In vitro and animal experiments have helped gather information, but human data on niacin/NAD status and skin cancer are severely limited. One study reported that niacin supplementation decreased the risk of ultraviolet light (UV)-induced skin cancers in mice, despite the fact that mice convert tryptophan to NAD more efficiently than rats and humans and thus do not get severely deficient (43).
  • Hyper-proliferation and impaired differentiation of skin cells can alter the integrity of the skin barrier and increase the occurrence of pre-malignant and malignant skin conditions. A protective effect of niacin was suggested by topical application of myristyl nicotinate, a niacin derivative, which successfully increased the expression of epidermal differentiation markers in subjects with photodamaged skin (44). The activation of the “niacin receptors,” GPR109A and GPR109B, by pharmacologic doses of niacin could be involved in improving skin barrier function. Conversely, differentiation defects in skin cancer cells were linked to the abnormal cellular localization of defective “niacin receptors” (45).
  • Nicotinamide restriction with subsequent depletion of cellular NAD was shown to increase oxidative stress-induced DNA damage in a precancerous skin cell model, implying a protective role of NAD-dependent pathways in cancer (46). Altered NAD availability also affects sirtuin expression and activity in UV-exposed human skin cells. Along with PARPs, NAD-consuming sirtuins could play an important role in the cellular response to photodamage and skin homeostasis (47).

Type 1 diabetes mellitus

  • Type 1 (insulin-dependent) diabetes mellitus in children is known to result from the autoimmune destruction of insulin-secreting β-cells in the pancreas. Prior to the onset of symptomatic diabetes, specific antibodies, including islet cell antibodies (ICA), can be detected in the blood of high-risk individuals. The ability to detect individuals at high risk for the development of IDDM led to the enrollment of high-risk siblings of children with IDDM into trials designed to prevent its onset. Evidence from in vitro and animal research indicates that high levels of nicotinamide protect β-cells from damage by toxic chemicals, inflammatory white blood cells, and reactive oxygen species. Pharmacologic doses of nicotinamide (up to 3 grams/day) were first used to protect β-cells in patients shortly after the onset of IDDM.
  • An analysis of 10 published trials (5 placebo-controlled) found evidence of improved β-cell function after one year of treatment with nicotinamide, but the analysis failed to find any clinical evidence of improved glycemic (blood glucose) control (48). However, high doses of nicotinamide could decrease insulin sensitivity in high-risk relatives of IDDM patients (49), which might explain the finding of improved β-cell function without concomitant improvement in glycemic control.

http://lpi.oregonstate.edu/mic/vitamins/niacin

https://en.wikipedia.org/wiki/Tryptophan

https://www.technologyreview.com/s/534636/the-anti-aging-pill/

Click to access bogan08.pdf

79% deaths from opioids pain med 2013-2014

opoid epi

It’s the first time in history that a Surgeon General has sent a letter directly to American physicians.

This is a major signal to doctors and the public that it’s time for something to be done about the thousands of Americans who are dying each year from overdosing on prescription painkillers like oxycodone, fentanyl, and morphine.

Between 2013 and 2014, deaths from synthetic opioids skyrocketed by 79%, according to a new CDC report released Thursday.

Since opioid painkillers slow breathing and act on the same brain systems as heroin, they carry serious risks of overdose and, in rarer cases, addiction. But cases that would normally be rare are happening with increasing regularity as the drugs are being given to so many people. Despite being home to just 5% of the world’s population, America consumes 80% of its opioids.

These drugs are powerful. Fentanyl, the drug that killed Prince, is roughly 50 times stronger than pure heroin. And although the deadly drug is legal with a doctor’s prescription, it’s also being made illegally in underground labs and traded across the US.

Still, doctors’ prescriptions are a sizeable part of the problem.

A 2014 report from the American Academy of Neurology estimates that more than 100,000 Americans have died from prescribed opioids since the late 1990s. Those at highest risk include people between 35 and 54, the report found, and deaths from opioids in this age group have exceeded those from firearms and car crashes.

” … As clinicians, we have the unique power to help end this epidemic,” Murthy wrote in his letter.

To make matters worse, the drugs are often prescribed alongside other drugs, like tranquilizers, that can raise the chances of accidental overdose and death. Yet they’re often prescribed together anyway.

In 2011, 31% of prescription opioid-related overdose deaths involved these two kinds of drugs used together, according to the National Institute on Drug Abuse. “Unfortunately, too many patients are still co-prescribed opioid pain relievers and benzodiazepines [tranquilizers],” the institute said.

Nurses identify 10 needs health startup should focus on

The following list was compiled from interviews with Sheila Antrum (president and senior vice-president, health adult services, UCSF Medical Center), Daphne Stannard (director and chief nurse researcher, Institute for Nursing Excellence, UCSF Medical Center), and Alberto Garcia (patient care director, health adult services,UCSF Medical Center).

Why are we sharing this? UCSF’s Center for Digital Health Innovation was formed three years ago to help improve patient care using technology, and we’d like to see more collaboration between health systems and entrepreneurs in health care. Please reach out to us if you’re working on any of these issues!

1. Patient and family navigation technology. Health systems employ many people as “navigators” to guide patients and their families from one location in a hospital or clinic to another. We like the idea of such technology that in addition to guiding patients through the hospital, helps patients and family members stay abreast of clinical updates. For example, for a patient getting surgery, the app would help guide the patient from the waiting area to the preoperative area and then would later alert the patient’s family members when the surgery has been completed. This solution relies on deep integration with existing hospital technologies, including the electronic health record (EHR) and hospital scheduling software.

2. Virtual hospital sitters. UCSF and other health systems spend millions of dollars each year hiring people to sit at the patient bedside to monitor for falls, self-harm, or other deleterious behaviors. If sitters could be partially replaced with robots or other virtual technology, UCSF could keep patients safe while saving huge amounts of money on workforce costs.

3. Artificial intelligence for the hospital. Advances in machine learning and artificial intelligence (AI) have opened the door for predictive modeling to enhance patient care. From ICU monitoring systems that model patients’ vital signs and produce patient-specific care recommendations, to identifying patterns in care that can have significant impacts on patient outcomes, the future potential for AI in health systems is substantial. Beyond the use of patient data, Sheila and her colleagues expressed interest in AI for the hospital environment – a system in which the environment adapts to patient needs. Such technology could be used for better managing inpatients with pain, delirium, or for promoting mobility for hospitalized patients.

4. Automated documentation within the electronic health record. It’s well accepted that both nurses and physicians spend too much time documenting in electronic health records (EHRs). Nurses, in particular, spend large amounts of time transcribing information from pumps and other patient devices to the EHR. Automated documentation between connected devices and the EHR would improve workforce efficiency and also allow hospitals to more quickly and accurately assess risky states for the institution and the patient, and optimize accordingly. Why hasn’t this happened already? EHR integration between devices is notoriously cumbersome, leaving nurses to take on this effort manually.

5. Virtual home-health communities. Telehealth is rightly a huge area of interest for healthcare innovation. But most telehealth companies are focused on 1:1 patient and provider visits. We see a future in which one provider is able to hold virtual group visits, for example for patients discharged from the hospital with similar conditions. Using population health management tools and the hospital discharge team, these patients could also be matched with a community of patients in their neighborhood, or connect with each other through a virtual platform with relevant resources and communication functions.

6. Price transparency tools for the inpatient setting. There needs to be a better way to track the costs patients face on an ongoing basis. In addition, price transparency tools need to interface with EHRs. Differing reimbursement offered by different plans to each health system have made this issue an ongoing challenge for patients and providers.

7. Pain management dashboard. Current stand-alone technologies exist for chronic disease management, but a pain management dashboard embedded within the EHR could lead to a better and safer tracking of patients with chronic pain issues. With the growing pain medicine epidemic, better and safer pain management is hugely important. Right now, pain management is a fragmented process, requiring patient, pharmacy, nursing, and provider input. An integrated dashboard that allows for cross checking with outpatient pharmacies and the CURES database, pain scoring, and ordering would help ease this currently manual process.

8. Technology to enable safe patient handling. Care teams constantly have to move, position, and lift patients —  even when they shouldn’t. And these tasks can be taxing to staff and result in significant hospital liabilities. Similarly, the safe handling of hospital waste is still a very manual process. Robotic technologies that automate these tasks are appealing from a time, cost, and safety perspective.

9. Research management application. For providers and care teams, it is difficult to know if a patient is enrolled in a clinical trial, which can create significant safety issues. For example, if a patient enrolled in a clinical study is admitted to the hospital and is administered a medication that interacts with a study drug, the patient could be at significant risk for a drug interaction. At present, there is no automated way of managing and flagging patients enrolled in trials. With a better research management application that connects to the EHR, an automated research interface would flag patients who are part of a trial and provide additional supporting materials regarding safety measures that must be followed.

10. Apps for frontline staff. Frontline nurses attend to almost all of a patient’s basic needs. In doing so, they often juggle up to 25 pieces of paper with critical information. Ideally, nurses could use charting software that would help manage and streamline all this information.


Motherhealth is looking for investing partners, doctors and developers for a Health Mobile Outpatient application that will match, monitor and report patient generated health data, including video chats with care providers, cancer care coordination analytics, genetic and lab tests health data sharing and more. Email Connie Dello Buono at motherhealth@gmail.com ; 1708 Hallmark Lane San Jose CA 95124

Proactive and engaged patients

A 42-year-old patient arrived for her annual gynecologist appointment complaining of a self-detected breast lump. She had several questions about her condition and wanted to tell her doctor about a family history of breast cancer.  The doctor was in a hurry and advised her to ask the staff, but the staff was busy with other patients and told her to call them later. The patient did not call.

The gynecologist ordered a mammogram but did not include the patient’s complaint of the breast lump on the requisition. The mammogram was read as “normal,” but the report noted a “very dense stromal pattern,” which reduces the sensitivity of the study for detection of cancer.  The radiologist did not recommend an ultrasound and described the mammogram as “normal” in the report to the gynecologist. No follow-up appointment was scheduled. Several months later, the patient scheduled another appointment with the gynecologist when she noticed the breast lump had increased in size.  Subsequently, she was diagnosed with breast cancer and scheduled for surgery.


Doctors and nurses should engage patients and encourage them to take charge and be proactive about their health. Each woman should know how to do a self-check for any abnormal breast tissues. Youtube can show you how. My nurse midwife told me how to. Use the palm part of your two fingers (middle), palpate your breast checking for lumps. Examine skin for any abnormal growth, itchiness,redness and discoloration. See a doctor and not a dermatologist for breast cases or skin disorders near the breast area.

Talk to your doctors for any abnormal skin issues or body aches and pain. Get a genetic tests to show to your doctor your family history and genetic test results.

Nurses and doctors should encourage more communication and knowledge sharing to prevent any emergencies or discover health issues early.